Status:
ACTIVE_NOT_RECRUITING
Aberrant Gene Expression Prostate Carcinoma
Lead Sponsor:
Lahey Clinic
Conditions:
Prostate Cancer
Eligibility:
MALE
Brief Summary
The goal of the study is to gain a better understanding of the molecular changes responsible for causing prostate cancer and that examination of tissue and blood samples will help in the development o...
Detailed Description
The goal of this study is to identify novel genetic elements that are aberantly expressed throughout prostatic neoplastic progression. The approaches proposed exploit the known familial arm of prostat...
Eligibility Criteria
Inclusion
- Diagnosed prostate cancer undergoing prostatectomy
- Suspicion of prostate cancer undergoing biopsy - negative biopsy
- Health volunteer (control group) - blood sample for PSA
Exclusion
- Patients not fitting the inclusion criteria
Key Trial Info
Start Date :
April 1 1995
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2030
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT00868803
Start Date
April 1 1995
End Date
April 1 2030
Last Update
June 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lahey Clinic
Burlington, Massachusetts, United States, 01805